These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 20694698)

  • 1. A natural products approach to drug discovery: probing modes of action of antitumor agents by genome-scale cDNA library screening.
    Luesch H; Abreu P
    Methods Mol Biol; 2009; 572():261-77. PubMed ID: 20694698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a high-content screening assay panel to accelerate mechanism of action studies for oncology research.
    Towne DL; Nicholl EE; Comess KM; Galasinski SC; Hajduk PJ; Abraham VC
    J Biomol Screen; 2012 Sep; 17(8):1005-17. PubMed ID: 22706350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing, optimizing, and implementing high-throughput siRNA genomic screening with glioma cells for the discovery of survival genes and novel drug targets.
    Thaker NG; McDonald PR; Zhang F; Kitchens CA; Shun TY; Pollack IF; Lazo JS
    J Neurosci Methods; 2010 Jan; 185(2):204-12. PubMed ID: 19782703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
    Bergsdorf C; Ottl J
    Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput RNAi screening for the identification of novel targets.
    Henderson MC; Azorsa DO
    Methods Mol Biol; 2013; 986():89-95. PubMed ID: 23436407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of combinatorial library methods in cancer research and drug discovery.
    Lam KS
    Anticancer Drug Des; 1997 Apr; 12(3):145-67. PubMed ID: 9154108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug design and testing: profiling of antiproliferative agents for cancer therapy using a cell-based methyl-[3H]-thymidine incorporation assay.
    Griffiths M; Sundaram H
    Methods Mol Biol; 2011; 731():451-65. PubMed ID: 21516428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing a high-throughput and automated cancer cell proliferation panel for oncology lead optimization.
    Lei M; Ribeiro H; Kolodin G; Gill J; Wang YS; Maloney D; Fan Y; Li S; Myer L; Beluch M; Zhang L; Schweizer L
    J Biomol Screen; 2013 Oct; 18(9):1043-53. PubMed ID: 23733846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yeast genomics and proteomics in drug discovery and target validation.
    Parsons AB; Geyer R; Hughes TR; Boone C
    Prog Cell Cycle Res; 2003; 5():159-66. PubMed ID: 14593709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postgenomic strategies in antibacterial drug discovery.
    Brötz-Oesterhelt H; Sass P
    Future Microbiol; 2010 Oct; 5(10):1553-79. PubMed ID: 21073314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cheminformatics approaches to analyze diversity in compound screening libraries.
    Akella LB; DeCaprio D
    Curr Opin Chem Biol; 2010 Jun; 14(3):325-30. PubMed ID: 20457001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic screening of phylomer peptide libraries derived from genome fragments to identify and validate new targets and therapeutics.
    Watt PM
    Future Med Chem; 2009 May; 1(2):257-65. PubMed ID: 21425969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D models of epithelial-mesenchymal transition in breast cancer metastasis: high-throughput screening assay development, validation, and pilot screen.
    Li Q; Chen C; Kapadia A; Zhou Q; Harper MK; Schaack J; LaBarbera DV
    J Biomol Screen; 2011 Feb; 16(2):141-54. PubMed ID: 21297102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and potency optimization of 2-amino-5-arylmethyl-1,3-thiazole derivatives as potential therapeutic agents for prostate cancer.
    Krasavin M; Karapetian R; Konstantinov I; Gezentsvey Y; Bukhryakov K; Godovykh E; Soldatkina O; Lavrovsky Y; Sosnov AV; Gakh AA
    Arch Pharm (Weinheim); 2009 Jul; 342(7):420-7. PubMed ID: 19544302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel drugs for promising targets.
    Martell RE; Brooks DG; Wang Y; Wilcoxen K
    Clin Ther; 2013 Sep; 35(9):1271-81. PubMed ID: 24054704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical modification and organelle-specific localization of orlistat-like natural-product-based probes.
    Yang PY; Liu K; Zhang C; Chen GY; Shen Y; Ngai MH; Lear MJ; Yao SQ
    Chem Asian J; 2011 Oct; 6(10):2762-75. PubMed ID: 21744505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
    Iljin K; Ketola K; Vainio P; Halonen P; Kohonen P; Fey V; Grafström RC; Perälä M; Kallioniemi O
    Clin Cancer Res; 2009 Oct; 15(19):6070-8. PubMed ID: 19789329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining the mode of action of bioactive compounds.
    Azad MA; Wright GD
    Bioorg Med Chem; 2012 Mar; 20(6):1929-39. PubMed ID: 22300885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
    Kong D; Yamori T
    Bioorg Med Chem; 2012 Mar; 20(6):1947-51. PubMed ID: 22336246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular approaches towards development of purified natural products and their structurally known derivatives as efficient anti-cancer drugs: current trends.
    Saha SK; Khuda-Bukhsh AR
    Eur J Pharmacol; 2013 Aug; 714(1-3):239-48. PubMed ID: 23819913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.